Global Transdermal Drug Delivery System Market is Estimated to be Valued at USD 8.1 Billion by 2026 End

  • 25 Sep 2019

Global transdermal drug delivery systems market is expected to reach a value of USD 8.1 billion by 2026 end, is predicted to register a CAGR of over 4% during the forecast period 2019 to 2026. The growth of this market has been determined by technological advancements and assessing the increase in the number of incidences of persistent diseases. 

 

The rising levels of chronic diseases and various technological developments have culminated in the pharmaceutical, biotechnology and healthcare sectors to push for an increase in transdermal drug delivery system market size.

 

The market is categorized on the basis of application as cardiovascular diseases central nervous system disorders, hormonal applications, pain management, amongst others. The segment relating to hormonal applications segment is bifurcated into the testosterone replacement therapies and transdermal estrogen. Pain management accounted for the largest share in the global market in 2018, owing to the increasing burden of persistent globally and increasing hiking the transdermal product accessibility for the use of pain management. 

 

The end user segment for the market is segregated into home care settings, clinics and hospitals. The home care settings segment accounted for the major share of the global market in 2018. 

North America held a major market share in the global market in the year 2018 and is predicted to take precedence during the forecast period. The escalating number of persistent illnesses and the increasing population levels have proven to be advantageous to the regional market. As per the CDC, it has been shown that for every three Americans, at least one of them will suffer from illnesses like high blood pressure. Furthermore, people who suffer from high blood pressure, account for only 54% and it is those same people who seem to be healthy. Furthermore, judging by the growing figures of transdermal drug delivery systems and increased usage of contraceptives, the regional market is expected to grow to new heights over the forecast period 

 

The European continent is ranked second concerning market share in the global transdermal drug delivery industry in 2018. A newly launched invention known as the accessible vapour patch entered the market in 2007. It was said to reduce smoking habits in Europe. 

 

The Asia pacific region has been estimated to fetch the highest growth rate globally. China and India accounted for the largest transdermal drug delivery market share in 2018 and are predicted to register a high CAGR during the forecast period. The increasing in the patient population in China and India and the prevalence of persistent diseases are factors responsible for the market growth of these countries. 

 

Additionally, the rise in healthcare expenditure along with expanding awareness of healthcare, and increased investments by different key players operating in the region for the development of innovative technologies has shown to be profitable for the regional market. It is worth noting that regions such as Latin America, Africa and the Middle East are placed at a very low scale in their shares within the transdermal drug delivery system market globally.

 

Key players included in the Transdermal Drug Delivery System Market are Hisamitsu Pharmaceutical (Japan), Mylan (US), UCB (Belgium), Novartis (Switzerland), GlaxoSmithKline (UK), Boehringer Ingelheim (Germany), Johnson & Johnson (US), Endo International (Ireland), and Purdue Pharma (US).

 

Competitive Landscape:

· There are rising levels of diseases such as that of chronic pain, cardiovascular diseases, central nervous systems disorders. Seeing how common these diseases are, has resulted in the increased use of contraceptives and has allowed for further research into the market of transdermal drug delivery systems.

· Transdermal drug delivery systems market has been identified as a profitable target market. This has resulted in there being many international players, such as Mylan, who manufature high quality innovative transdermal drug delivery systems, such as adhesive patches.

 

Global Transdermal Drug Delivery System Segmentation: -

By Product 

·Transdermal Patches  

·Transdermal Semisolids

 

By End User 

· Hospitals & Cardiac Centers 

· Ambulatory Surgery Centers 

 

By Region 

·North America 

· Europe 

·Asia Pacific 

·Rest of the World

 

FutureWise Key Takeaways:

• Growth prospects

• SWOT analysis 

• Key trends 

• Key data-points affecting market growth 

 

Objectives of the Study: 

· To provide an exhaustive analysis on the global transdermal drug delivery system market based on the offering, process, end users and region 

 · To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) 

 · To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, and the rest of the world

 · To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions 

 · Profiling of companies to evaluate their market shares, strategies, financials and core competencies  

 ·To evaluate and forecast micro-markets and the overall market 

 

Get unlimited analyst support and customise this study further to your requirements, contact sales@futurewiseresearch.com